Edition:
United States

People: Seattle Genetics Inc (SGEN.OQ)

SGEN.OQ on NASDAQ Stock Exchange Global Select Market

56.00USD
3:59pm EST
Change (% chg)

$-2.63 (-4.49%)
Prev Close
$58.63
Open
$59.18
Day's High
$59.18
Day's Low
$54.73
Volume
394,246
Avg. Vol
325,012
52-wk High
$84.35
52-wk Low
$47.79

Simpson, Todd 

Mr. Todd E. Simpson is the Chief Financial Officer of Seattle Genetics, Inc. Previously, Mr. Simpson served from October 2001 to October 2005 as Vice President, Finance & Administration and Chief Financial Officer of Targeted Genetics Corporation, a biotechnology company. From January 1996 to October 2001, Mr. Simpson served as Vice President, Finance & Administration and CFO of Aastrom Biosciences, Inc., a biotechnology company. From August 1995 to December 1995, he served as Treasurer of Integra LifeSciences Corporation, a biotechnology company, which acquired Telios Pharmaceuticals, Inc., in August 1995. From 1992 until its acquisition by Integra, he served as Vice President of Finance and CFO of Telios and in various other finance-related positions. Mr. Simpson is a certified public accountant, and from 1983 to 1992 he practiced public accounting with the firm of Ernst & Young LLP. Mr. Simpson currently serves on the board of directors of Aquinox Pharmaceuticals, Inc., a publicly-traded pharmaceutical company, and on the executive committee of the board of directors of Life Sciences Washington. Mr. Simpson received a B.S. in Accounting and Computer Science from Oregon State University.

Basic Compensation

Total Annual Compensation, USD 756,284
Restricted Stock Awards, USD 1,191,510
Long-Term Incentive Plans, USD --
All Other, USD 1,114,000
Fiscal Year Total, USD 3,061,800

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 168,332 4,120,820.00
Name Fiscal Year Total

Clay Siegall

8,616,340

Todd Simpson

3,061,800

Jean Liu

2,399,940

Darren Cline

--

Vaughn Himes

2,760,340

Felix Baker

575,165
As Of  30 Dec 2017